Cargando…
Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease
At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment o...
Autores principales: | Berger, Thomas, Adamczyk-Sowa, Monika, Csépány, Tünde, Fazekas, Franz, Fabjan, Tanja Hojs, Horáková, Dana, Ledinek, Alenka Horvat, Illes, Zsolt, Kobelt, Gisela, Jazbec, Saša Šega, Klímová, Eleonóra, Leutmezer, Fritz, Rejdak, Konrad, Rozsa, Csilla, Sellner, Johann, Selmaj, Krzysztof, Štouracˇ, Pavel, Szilasiová, Jarmila, Turcˇáni, Peter, Vachová, Marta, Vanecková, Manuela, Vécsei, László, Havrdová, Eva Kubala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724259/ https://www.ncbi.nlm.nih.gov/pubmed/33335562 http://dx.doi.org/10.1177/1756286420975223 |
Ejemplares similares
-
Management of multiple sclerosis patients in central European countries: current needs and potential solutions
por: Berger, Thomas, et al.
Publicado: (2018) -
How Does Fingolimod (Gilenya(®)) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
por: Fazekas, Franz, et al.
Publicado: (2013) -
Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021) -
Real-Life Outcome in Multiple Sclerosis in the Czech Republic
por: Kobelt, Gisela, et al.
Publicado: (2019) -
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
por: Uher, Tomas, et al.
Publicado: (2021)